Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine

Journal of Diabetes Science and Technology

Volumn 3, Issue 4, 2009, Pages 743-747

  Mark, W ^a  

^a Lackland AFB ^*  (United States)

Author keywords

1,5 anhydroglucitol; Diabetes biomarkers; Glycation gap; Hemoglobin A1c variability; Hemoglobin glycation index; Personalized medicine

Indexed keywords

1,5 ANHYDROSORBITOL; 1,5-ANHYDROGLUCITOL; BIOLOGICAL MARKER; DEOXYGLUCOSE; FRUCTOSAMINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BLOOD; DIABETES MELLITUS; HUMAN; METABOLISM; PERSONALIZED MEDICINE; REVIEW;

BIOLOGICAL MARKERS; DEOXYGLUCOSE; DIABETES MELLITUS; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 77953073717     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300421     Document Type: Conference Paper

References (25)

1. Kilpatrick ES. Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus. J Clin Pathol. 2008;61(9):977-82.
2. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, Sacks DB. Tests of glycemia in diabetes. Diabetes Care. 2004;27(7):1761-73. (Pubitemid 38857461)
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
5. Stratton IM, Adler AL, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12. (Pubitemid 30609442)
6. The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
7. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med. 2008;358(24):2560-72.
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39.
9. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care. 2003;26(10):2728-33.
10. National Diabetes Information Clearinghouse. Sickle cell trait and other hemoglobinopathies and diabetes: important information for physicians. Updated November 2007. http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/. Accessed March 10, 2009.
11. National Glycohemoglobin Standardization Program. Updated February 2009. http://www.ngsp. org. Accessed March 10, 2009.
12. The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care. 2007;30(9):2399-400.
13. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-8.
14. American Diabetes Association. Use of the estimated average glucose (eAG) in patient care. Updated February 2009. http://professional.diabetes.org/ Content/eAGPowerpointSlides.ppt. Accessed March 10, 2009.
15. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E, Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care. 2007;30(10):2453-7. (Pubitemid 47547771)
16. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259-64. (Pubitemid 38679967)
17. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes. 2007;56(7):1913-21. (Pubitemid 47025457)
18. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RD. HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes. 2001;50(12):2858-63. (Pubitemid 33733139)
19. Lindsey CC, Carter AW, Mangum S, Greene D, Richardson A, Brown SJ, Essary JL, McCandless B. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care. Diabetes Technol Ther. 2004;6(3):370-7. (Pubitemid 38821623)
20. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003;26(1):163-7. (Pubitemid 36929010)
21. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Hawa MI, Blinko S, Edwards R, Spector TD, Leslie RD. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care. 2006;29(8):1739-43. (Pubitemid 44156623)
22. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther. 2003;5(3):355-63. (Pubitemid 36676309)
23. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S. Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes. 1991;40(1):52-7.
24. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214-9. (Pubitemid 44125912)
25. Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9-19.